Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Director Sells $38,415.51 in Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the completion of the sale, the director now owns 13,356 shares of the company’s stock, valued at approximately $112,591.08. The trade was a 25.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aurinia Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:AUPH opened at $8.33 on Friday. The business has a 50-day moving average of $7.22 and a two-hundred day moving average of $6.19. Aurinia Pharmaceuticals Inc. has a fifty-two week low of $4.71 and a fifty-two week high of $10.05. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $10.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC boosted its position in Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock worth $4,015,000 after purchasing an additional 535,301 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the third quarter worth $3,330,000. Stonepine Capital Management LLC bought a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $1,713,000. AQR Capital Management LLC acquired a new position in Aurinia Pharmaceuticals in the 2nd quarter valued at $1,155,000. Finally, PDT Partners LLC grew its stake in Aurinia Pharmaceuticals by 76.0% in the 3rd quarter. PDT Partners LLC now owns 301,553 shares of the biotechnology company’s stock valued at $2,210,000 after buying an additional 130,204 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.